Home Therapeutics Pain

Pain

Latest
FENTANYL
Pain

Opiant Eyes Q2 Launch for Pivotal Trial of Opioid Overdose Candidate...

neuron in the mouse brain
Pain

Neurons Controlled Using Anti-Smoking Drug

Pain

Merck, King’s Launch $344M+ Chronic Pain Drug Collaboration

Pain

Aptinyx Weighs Lead Candidate’s Development in Chronic Pain after Phase II...

Pain

Why Some Injuries Are More Painful than Others

Nexium (esomeprazole)
Pain

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M

Molecule structure drawn on board
Pain

Lilly, Dicerna Launch $3.7B+ RNAi Collaboration

Insys Therapeutics says it will ponder its next steps following FDA rejection of its new drug application (NDA) for Buvaya (buprenorphine sublingual spray) as a treatment for moderate-to-severe acute pain.
Pain

Insys Weighs Next Steps after FDA Rejects NDA for Acute Pain...

Pain

Aquinox Axes Half its Workforce after Phase III Failure of Lead...

Teva Pharmaceutical Industries is halting a Phase III trial of fremanezumab (TEV-48125) for chronic cluster headaches
Pain

Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches

Load more

Recently Featured

Stay Connected

557,107FansLike
47,032FollowersFollow
Copyright © 2019 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up